☰
✕

Chronic kidney disease drugs market

Chronic Kidney Disease Drugs Market, by Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), B-Blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, and others), by Route of Administration (Oral, Subcutaneous, Intravenous), by Patient Type (Dialysis, Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample
  • Oct 2022
  • CMI1713
  • 206 Pages
  • Excel & Pdf
  • Pharmaceutical

Chronic kidney disease includes conditions that damage kidneys and decrease their ability to keep you healthy by filtering wastes from blood. The symptoms of chronic kidney disease includes:

  • Have Trouble Concentrating
  • Poor Appetite
  • Swollen Feet And Ankles
  • Dry and itchy skin
  • Need to urinate more often, especially at night and others

Chronic kidney can be treated using drug class such as: ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), B-Blockers, Calcium Channel Blockers and others.

Global chronic kidney disease drugs market is estimated to be valued at US$ 13, 220.0 million in 2022 and is expected to exhibit a CAGR of 4.5% during the forecast period (2022-2030).

Figure 1. Global Chronic Kidney Disease Drugs Market Share (%), by Drug Class, 2022

Global Chronic Kidney Disease Drugs Market- Drivers

Increasing number of drug approvals by regulatory bodies is expected to drive the global chronic kidney disease drugs market growth over the forecast period.

Increasing number of drug approvals by regulatory bodies is expected to boost the growth of global chronic kidney disease drugs market. For instance, On June 30, 2022, Bayer AG, a pharmaceutical company, announced that the Chinese National Medical Products Administration (NMPA) had granted marketing authorization for Finerenone under the brand name Kerendia. Kerendia (10 mg or 20 mg), a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is indicated for the treatment of chronic kidney disease (CKD).

Furthermore, In August 2021, AstraZeneca plc., a biopharmaceutical company, announced that Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). 

Chronic Kidney Disease Drugs Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 13,220.0 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 4.5% 2030 Value Projection: US$ 17,832.5 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), B-Blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Others
  • By Route of Administration: Oral, Subcutaneous, Intravenous
  • By Patient Type: Dialysis, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd.
Growth Drivers:
  • Increasing prevalence of chronic kidney diseases
  • Product approvals and launches for the treatment of chronic kidney diseases
  • Adoption of inorganic strategies by market players
Restraints & Challenges:
  • Lack of awareness about chronic kidney diseases

Figure 2. Global Chronic Kidney Disease Drugs Market Share (%), by Region, 2022

Global Chronic Kidney Disease Drugs Market- Driver

Ongoing research and development of novel treatment for chronic kidney disease is expected to drive the global chronic kidney disease drugs market growth.

Manufacturers operating in the global chronic kidney disease drugs market are focusing on the development of novel treatments for chronic kidney disease. For instance, in September 2018, Reata Pharmaceuticals, Inc., a pharmaceutical company, announced positive results from type 1 diabetic chronic kidney disease (T1D CKD) and IgA nephropathy cohorts of a Phase 2 study, PHOENIX, evaluating bardoxolone methyl (bardoxolone) in patients with rare forms of chronic kidney disease (CKD).

Moreover, in September 2019, Ardelyx, Inc. announced positive results from its phase 3 study, AMPLIFY, for tenapanor in combination with phosphate binders for patients with chronic kidney disease (CKD) on dialysis whose hyperphosphatemia was not previously controlled with binders alone.

Thus, the increasing focus of manufacturers on the development of novel products for the treatment of chronic kidney disease is posing a robust growth opportunity for the global chronic kidney disease drugs market

Global Chronic Kidney Disease Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic has drastically affected clinical trials. Many trials have paused enrollment and researchers are facing multiple challenges associated with setting up remote visits, and performing laboratory and other study assessments.

According to a survey conducted by Medidata Solutions, Inc. (an American technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies globally. The U.S. Food and Drug Administration (FDA) released guidelines on conducting clinical trials of medical products during the COVID-19 public health emergency in March 2020. The guidelines were further updated on July 02, 2020. The guidelines issued by the U.S. Food and Drug Administration (FDA) include general considerations to assist sponsors and researchers, which ensure the safety of trial participants, and compliance with good clinical practice (GCP) for the duration of the COVID-19 public health emergency.

The appendix of the guidelines also provide answers to some general questions, which the U.S. Food and Drug Administration (FDA) received from various sponsors and researchers about conducting clinical trials during the COVID-19 public health emergency.

Furthermore, healthcare facilities and researchers are adhering to the following safety measures for ongoing clinical trials:

The healthcare providers obtain consent from patients over the phone or through video conferences. According to a survey conducted by Medidata Solutions, Inc., on April 23, 2020, 45% respondents opted for virtual/telemedicine for consultancy.

The patients receive a phone call for screening of COVID-19 symptoms before the scheduled in-person visits. However, market players and research institutes are focusing on initiating clinical trials associated with COVID-19 in order to understand the effects of chronic kidney disease treatment drugs on patients suffering with COVID-19.

For instance, on July 28, 2020, Reata Pharmaceuticals, Inc. announced that researchers at the New York University (NYU) Grossman School of Medicine will be are initiating an Investigator-Sponsored Trial (IST), BARCONA, to study the effect of bardoxolone methyl (bardoxolone) in patients suffering from COVID-19 and Reata Pharmaceuticals, Inc., is providing the drug supply for the trial.

Global Chronic Kidney Disease Drugs Market: Key Developments

In July 2022, Grupo Olmos, a provider of renal care solutions, announced that the company had acquired renal care business of Diaverum, a renal healthcare provider, which operates in Argentina. The acquisition of renal business will strengthen the renal product portfolio of the company.

In March 2019, Aster Hospitals, the largest private healthcare service providers operating in multiple GCC states, announced that it had launched an awareness and screening initiative to promote the prevention of chronic kidney disease (CKD) through education, awareness, and early diagnosis.

Global Chronic Kidney Disease Drugs Market: Restraint

Lack of awareness of chronic kidney disease is expected to hinder the growth of global chronic kidney disease drugs market. An earlier diagnosis of chronic kidney disease (CKD) could slow the disease progression, prevent complications, and reduce cardiovascular-related outcomes. Early referral to a nephrologist has also been shown to improve outcomes for those who progress to end-stage renal disease. In March 2018, a cross-sectional study was published in BMC Public Health, according to which people in Australia have very poor understanding of chronic kidney disease (CKD) and only half of the participants knew that medications can help slow the worsening of CKD.  Furthermore, only 23.4% of participants knew that herbal supplements are ineffective in treating CKD.

Key Players

Major players operating in the global chronic kidney disease drugs market include Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Class
      • Market Snapshot, By Route Of Administration
      • Market Snapshot, By Patient Type
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Regulatory Scenario
    • Key Highlights
    • Research and Development
    • Collaboration, Mergers, and Acquisitions Scenario
    • Key Development
    • Recent Product Approvals and Launches
    • PEST Analysis
    • Pipeline Analysis
    • Epidemiology
  4. Global Chronic Kidney Disease Drugs Market- Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Impact on the market
    • Impact on Global Chronic Kidney Disease Drugs Market
    • Impact on Clinical Trials
  5. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • ACE Inhibitors
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Angiotensin Receptor Blockers (ARBs)
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • B-Blockers
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Calcium Channel Blockers
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Loop Diuretics
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Erythropoiesis-Stimulating Agents (ESAs)
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Phosphate Binders
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Others
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  6. Global Chronic Kidney Disease Drugs Market, By Route Of Administration, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Oral
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Subcutaneous
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Intravenous
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  7. Global Chronic Kidney Disease Drugs Market, By Patient Type, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Dialysis
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Others
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  8. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Online Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  9. Global Chronic Kidney Disease Drugs Market, By Region, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2030
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Type  2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Type  2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Type  2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Type  2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Type  2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Type  2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
  10. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Sanofi
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • AstraZeneca plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Amgen, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Regeneron Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • ProKidney Corp.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Kissei Pharmaceutical Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Reata Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Ardelyx, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Boehringer Ingelheim International GmbH
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novo Nordisk A/S
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Astellas Pharma Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Kibow Biotech, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • FibroGen, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Cara Therapeutics
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pieris Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Mitsubishi Chemical Group Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pharmacosmos A/S
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • OPKO Health, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Covis Pharma
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Tricida, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Biosidus S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • YUHAN
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Caladrius Biosciences, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • UnicoCell Biomed CO. LTD.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Akebia Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Caladrius Biosciences, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Allena Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • KBP Biosciences Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  11. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 32 market data tables and 26 figures on "Global Chronic Kidney Disease Drugs Market” - forecast to 2030

Detailed Segmentation:

  • Global Chronic Kidney Disease Drugs Market, By Drug Class:
    • ACE Inhibitors
    • Angiotensin Receptor Blockers (ARBs)
    • B-Blockers
    • Calcium Channel Blockers
    • Loop Diuretics
    • Erythropoiesis-Stimulating Agents (ESAs)
    • Phosphate Binders
    • Others
  • Global Chronic Kidney Disease Drugs Market, By Route of Administration:
    • Oral
    • Subcutaneous
    • Intravenous
  • Global Chronic Kidney Disease Drugs Market, By Patient Type:
    • Dialysis
    • Others
  • Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies 
    • Online Pharmacies
  • Global Chronic Kidney Disease Drugs Market, By Region:
    • North America
      • By Drug Class
        • ACE Inhibitors
        • Angiotensin Receptor Blockers (ARBs)
        • B-Blockers
        • Calcium Channel Blockers
        • Loop Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Phosphate Binders
        • Others
      • By Route of Administration
        • Oral
        • Subcutaneous
        • Intravenous
      • By Patient Type
        • Dialysis
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Class
        • ACE Inhibitors
        • Angiotensin Receptor Blockers (ARBs)
        • B-Blockers
        • Calcium Channel Blockers
        • Loop Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Phosphate Binders
        • Others
      • By Route of Administration
        • Oral
        • Subcutaneous
        • Intravenous
      • By Patient Type
        • Dialysis
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class
        • ACE Inhibitors
        • Angiotensin Receptor Blockers (ARBs)
        • B-Blockers
        • Calcium Channel Blockers
        • Loop Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Phosphate Binders
        • Others
      • By Route of Administration
        • Oral
        • Subcutaneous
        • Intravenous
      • By Patient Type
        • Dialysis
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class
        • ACE Inhibitors
        • Angiotensin Receptor Blockers (ARBs)
        • B-Blockers
        • Calcium Channel Blockers
        • Loop Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Phosphate Binders
        • Others
      • By Route of Administration
        • Oral
        • Subcutaneous
        • Intravenous
      • By Patient Type
        • Dialysis
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class
        • ACE Inhibitors
        • Angiotensin Receptor Blockers (ARBs)
        • B-Blockers
        • Calcium Channel Blockers
        • Loop Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Phosphate Binders
        • Others
      • By Route of Administration
        • Oral
        • Subcutaneous
        • Intravenous
      • By Patient Type
        • Dialysis
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class
        • ACE Inhibitors
        • Angiotensin Receptor Blockers (ARBs)
        • B-Blockers
        • Calcium Channel Blockers
        • Loop Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Phosphate Binders
        • Others
      • By Route of Administration
        • Oral
        • Subcutaneous
        • Intravenous
      • By Patient Type
        • Dialysis
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2020-2027)?

The global chronic kidney disease drugs market is estimated to be valued at US$ 12,328.2 million in 2020 and is expected to exhibit a CAGR of 4.0% between 2020 and 2027.

What are the major factors driving the Chronic Kidney Disease Drugs market growth?

The increasing prevalence of chronic kidney disease across the globe, increasing launch & approval of products for CKD treatment, and adoption of inorganic growth strategies such as merger, acquisition, & collaboration by market players are expected to drive the market growth over the forecast period.

Which is the leading drug type segment in the Chronic Kidney Disease Drugs market?

Erythropoiesis-stimulating Agents (ESAs) is the leading drug type segment in the chronic kidney disease drugs market.

Which region holds the largest market share in the Chronic Kidney Disease Drugs market?

North America is expected to hold the largest market share in the global chronic kidney disease drugs market.

What are the key factors hampering growth of the market?

Lack of awareness about chronic kidney disease is the major factor that is expected to restrain growth of the chronic kidney disease drugs market.

Which are the major players operating in the market?

Major players operating in the global chronic kidney disease drugs market include Amgen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, Hoffmann La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Reata Pharmaceuticals, Inc., GlaxoSmithKline Plc, and Ardelyx, Inc.
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Buy Now with Special Discount
Customize Now